Bakhu Holdings, Corp. Stock: price and management transactions · United States · SEC (Form 4)

About Bakhu Holdings, Corp.

Bakhu Holdings, Corp. is a U.S.-based company with its common stock quoted on OTC Markets under the ticker BKUH; based on the SEC filings reviewed, it is not listed on NYSE or NASDAQ at this time. The company is organized in the United States, with an operating address in Long Beach, California. It was incorporated in 2008 and changed its name in 2009 from Planet Resources, Corp. to Bakhu Holdings, Corp., before pivoting toward cannabis-related technology. From an operating perspective, Bakhu is best understood as a technology-licensing and development-stage company rather than a conventional cannabis cultivator or retailer. Its SEC filings describe a license from Cell Science covering plant cell-extraction and replication technology, together with related proprietary equipment, processes, and formulations. The intended use of that licensed science is to produce, manufacture, and sell cannabis-related byproducts, including cannabinoids, for medical, food additive, and recreational applications in jurisdictions where such activities are lawful. The company has also stated that it does not itself intend to directly produce, transport, or sell cannabis products at scale; instead, commercialization is expected to occur through strategic partners, joint ventures, or sublicensees. Bakhu’s business lines therefore remain concentrated on intellectual-property monetization, funding execution, and commercial partnership development. Its competitive position is that of a niche technology platform in a highly fragmented, highly regulated cannabis ecosystem. That positioning can be attractive if the technology proves scalable and partner-led commercialization gains traction, but it also comes with elevated execution risk, financing dependence, and regulatory uncertainty. The company is not currently presented as a vertically integrated multi-state operator; rather, its value proposition rests on whether its cell-based replication approach can be translated into repeatable commercial production. Recent developments reinforce that profile. In February 2024, Bakhu announced the closing of an initial tranche of secured convertible notes carrying 13% interest, with maturity in February 2028, and referenced external funding capacity of up to $20 million. The company also disclosed extensions of certain debt maturities tied to its technology license arrangement. For investors in the United States and abroad, Bakhu Holdings should therefore be viewed as a highly speculative micro-cap cannabis technology story whose investment case depends on financing, regulatory permissibility, and the ability to convert licensed science into commercial revenue.